Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.09% | 4.76% | |||
| Total Other Revenue | 57.09% | 9.28% | |||
| Total Revenue | 1.84% | 4.89% | |||
| Cost of Revenue | 12.19% | 192.50% | |||
| Gross Profit | -7.48% | -33.50% | |||
| SG&A Expenses | 10.89% | -5.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.82% | 0.95% | |||
| Operating Income | -18.03% | 13.74% | |||
| Income Before Tax | -35.83% | -8.30% | |||
| Income Tax Expenses | -73.49% | -22.17% | |||
| Earnings from Continuing Operations | -31.55% | -6.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.55% | -6.40% | |||
| EBIT | -18.03% | 13.74% | |||
| EBITDA | -16.08% | 12.45% | |||
| EPS Basic | -31.23% | -6.40% | |||
| Normalized Basic EPS | -15.23% | 12.96% | |||
| EPS Diluted | -30.07% | -7.01% | |||
| Normalized Diluted EPS | -13.84% | 12.18% | |||
| Average Basic Shares Outstanding | -0.46% | 0.00% | |||
| Average Diluted Shares Outstanding | -2.07% | 0.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
